glp-1 stories Queer Eye's Jonathan Van Ness credits medication for 66-pound weight loss 6 Months of Weight Loss
Description
FDA labeling for Wegovy (semaglutide) lists common adverse reactions such as nausea, vomiting, diarrhea, constipation, abdominal pain, reflux/GERD, abdominal distension, and flatulence
Novo Nordisk made its oral version of Wegovy available in January 2026 after a clinical trial funded by the drug company showed that the pills were about as effective as injectables
Notably, after receiving LG, most patients showed improvements in steatosis and hepatocyte ballooning
There haven' been any human studies on breastfed infants and milk production to really know the possible side effects and infant risk/infant health
